Association between CDH1 methylation and esophageal cancer risk: a meta-analysis and bioinformatics study. (2nd September 2022)

• Record Type: Journal Article
• Authors: Fan, Zhiyuan; Chen, Ru; Li, Minjuan; Gu, Jianhua; Li, Xinqing; Wei, Wenqiang
• Is Part Of: Expert review of molecular diagnostics. Volume 22:Number 9(2022)
• Page Start: 895
• Page End: 903
• Publication Date: 2022-09-02
• Subjects: CDH1 methylation -- esophageal cancer -- diagnosis -- biomarker -- meta-analysis -- bioinformatics study; Molecular diagnosis -- Periodicals; 616.0758205
• DOI: 10.1080/14737159.2022.2132853
• Languages: English
• ISSNs: 1473-7159

Abstract

ABSTRACT: Objective: The aim is to evaluate the association of CDH1 methylation with esophageal cancer (EC) risk. Methods: The PubMed, Embase, Web of Science, and Cochrane Library databases were systematically searched to identify relevant articles. Pooled odds ratios (ORs) with 95% confidence interval (CI) were estimated using the fixed- or random-effects models. The pooled sensitivity and specificity were calculated to assess the diagnostic value of CDH1 methylation for EC. The results of the meta-analysis were validated using The Cancer Genome Atlas and Gene Expression Omnibus databases. Results: Thirteen studies consisting of 1, 633 samples were included. A high CDH1 methylation was significantly associated with an increased risk of EC (OR = 10.40, 95% CI = 6.29–17.18). Furthermore, CDH1 methylation status was related to tumor status, lymph node status, and metastasis. For the diagnosis of EC, the pooled sensitivity and specificity of CDH1 methylation were 0.57 (95% CI = 0.39–0.74) and 0.89 (95% CI = 0.81–0.94), respectively. Bioinformatics analysis showed that CDH1 methylation occurred more frequently in EC tissues than in normal controls, in good agreement with the results of the meta-analysis. Conclusion: A significant association was found between CDH1 methylation and EC risk. We therefore suggest that CDH1 methylation can serve as a promising diagnostic marker for EC.